UroGen Pharma Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Feb '26 Feb 27, 2026	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Market Capitalization	994	449	463	205	213	398
Market Cap Growth	119.42%	-2.93%	126.06%	-3.94%	-46.44%	-43.13%
Enterprise Value	978	318	409	184	105	276
Last Close Price	21.18	10.65	15.00	8.87	9.51	18.02
PS Ratio	10.11	4.97	5.60	3.18	4.44	33.74
PB Ratio	-	-51.05	-7.10	-2.29	25.34	4.13
P/TBV Ratio	-	-	-	-	25.34	4.13
EV/Sales Ratio	10.14	3.52	4.95	2.85	2.18	23.36
Debt / Equity Ratio	-1.13	-14.19	-1.54	-1.12	0.18	0.03
Net Debt / Equity Ratio	-0.02	13.27	0.63	0.00	-10.50	-1.05
Net Debt / EBITDA Ratio	-0.02	1.23	0.64	0.00	0.97	0.85
Net Debt / FCF Ratio	-0.02	1.20	0.54	0.00	1.03	0.95
Asset Turnover	0.40	0.39	0.53	0.50	0.40	0.07
Inventory Turnover	1.46	1.19	1.87	1.67	1.52	-
Quick Ratio	3.47	5.59	4.88	4.71	4.51	5.09
Current Ratio	3.99	6.01	5.42	5.39	5.11	5.39
Return on Equity (ROE)	-	-	-	-	-211.55%	-92.88%
Return on Assets (ROA)	-33.96%	-25.77%	-26.10%	-38.69%	-47.72%	-46.29%
Return on Capital Employed (ROCE)	-92.60%	-39.90%	-44.60%	-70.80%	-94.80%	-119.50%
Earnings Yield	-16.87%	-28.23%	-22.08%	-53.60%	-51.98%	-32.27%
FCF Yield	-14.15%	-21.60%	-16.54%	-42.88%	-40.17%	-26.90%
Buyback Yield / Dilution	-18.43%	-48.70%	-26.43%	-2.05%	-2.60%	-6.10%

Updated Nov 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q